v

VAN DOORN R.

Last name: VAN DOORN R.

2021 (v1)

Publication

Metadata-only

Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants

Spagnolo F. Dalmasso B. Tanda E.

Inherited pathogenic variants (PVs) in the CDKN2A tumor suppressor gene are among the strongest risk factors for cutaneous melanoma. Dysregulation of the p16/RB1 pathway may intrinsically limit the activity of MAPK‐directed therapy due to the interplay between the two pathways. In our study, we assessed, for the first time, whether patients...

Uploaded on: April 14, 2023